Company Overview
American HealthCare Capital is pleased to exclusively introduce a U.S.-based neuro-rehabilitation technology developer, distributor, and clinical-support business serving rehabilitation providers, O&P settings, post-acute care environments, and patients. Its offering includes a portfolio of rehabilitation technologies, clinical support and education, and proprietary and licensed mobility initiatives in body-weight-supported gait training and ankle neuromodulation.
Financial Overview
The Company reported 2025 accrual-basis revenue of approximately $0.7 million, gross profit of approximately $0.5 million and net income of approximately $0.2 million. Revenue increased by approximately 40% from 2024 to 2025. 2026 numbers are aligned with 2025 results, and the management creating the base to scale the company further in the coming years.
Key Platform and Business Highlights
- Multi-channel commercialization model spanning direct sales, distribution, e-commerce, clinical support, and education.
- Access to rehabilitation, O&P, post-acute, outpatient, and patient markets, with international distributor activity in LATAM and the Middle East.
- A patented mobility platform designed for modular, body-weight-supported gait and balance training, with accessories and multiple use settings.
- The license to three patents for an ankle neuromodulation development initiative with stated intellectual-property and regulatory-development dependencies.
- Founder-led organization with a small core team and clinical-specialist contractor support.
Growth and Scalability Opportunities
- Expand distribution through an acquirer’s established clinical, provider, O&P, DME, mobility, online rehab catalog companies, or post-acute channels.
- Cross-sell an expanding portfolio of products, accessories, training, and support into a broader installed base.
- Gain operating leverage through shared procurement, logistics, regulatory, quality, sales operations, and customer-success capabilities.
- Advance product development, clinical validation, and regulatory pathways with strategic resources.
Strategic Buyer Rationale
The Company may be relevant to strategic medical-device, rehabilitation, mobility, O&P, DME, post-acute, provider, healthcare-services, and technology-enabled platforms seeking a clinically oriented distribution and product capability. Potential value creation is linked to current revenue base, product economics, IP and regulatory rights, channel contracts, product claims, inventory, and management continuity.
Transaction Overview
The Seller is open to majority control sale to accelerate scaling, valuation, seller rollover, and timing are to be confirmed in diligence, discussed, and negotiated. Management has indicated a willingness to remain with the Company if requested.
Asking Price
The asking price shall be determined through discussion and negotiation.